Holen Sie sich die Stockscreener-App
27.21
1.27%
-0.35
Handel nachbörslich:
27.20
-0.01
-0.04%
Schlusskurs vom Vortag:
$27.56
Offen:
$27.42
24-Stunden-Volumen:
870.48K
Relative Volume:
0.84
Marktkapitalisierung:
$1.62B
Einnahmen:
$66.05M
Nettoeinkommen (Verlust:
$-422.60M
KGV:
-3.7526
EPS:
-7.251
Netto-Cashflow:
$-384.73M
1W Leistung:
+9.72%
1M Leistung:
-22.70%
6M Leistung:
-32.83%
1J Leistung:
-9.21%
1-Tages-Spanne:
$26.93
$28.00
1-Wochen-Bereich:
$25.65
$28.82
52-Wochen-Spanne:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.21 | 1.64B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Bestätigt | H.C. Wainwright | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues - 富途牛牛
AGIO beats on Q1 earnings & sales, stock up 13% on new drug momentum - MSN
Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress - IndexBox
Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration NewsHas The Bull Case Changed? - Sahm
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) - The Motley Fool
RBC Capital Sticks to Its Hold Rating for Agios Pharma (AGIO) - The Globe and Mail
MSN Money - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Agios Pharmaceuticals Hits Day High with 13.1% Surge in Stock Price - Markets Mojo
Agios Pharmaceuticals Reports 20.7 Million Dollars in Q1 Revenue - HarianBasis.co
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum - The Globe and Mail
Agios (AGIO) Q1 2026 Earnings Call Transcript - AOL.com
AGIO Maintained by Truist Securities -- Price Target Lowered to $36 - GuruFocus
Truist Financial Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat
Agios Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
(AGIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Agios Pharmaceuticals Inc (AGIO) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic Advances - GuruFocus
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
AGIO SEC FilingsAgios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Agios Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) 2026-04-29 - Seeking Alpha
Agios Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday - Yahoo Finance
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday - The Motley Fool
Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN
Earnings Call Summary | Agios Pharmaceuticals(AGIO.US) Q1 2026 Earnings Conference - 富途牛牛
Vanguard Capital Management (NASDAQ: AGIO) reports 3.09M shares, 5.27% ownership - Stock Titan
Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Agios Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Agios Pharmaceuticals : 2026 Proxy Statement (a7ac5c) - marketscreener.com
AGIO Financials: Income Statement, Balance Sheet & Cash Flow | Agios Pharmaceuticals Inc - Stock Titan
Agios Pharmaceuticals Q1 2026 Financial Results: Net Loss, Revenue, and Key Financial Statements - Minichart
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Earnings Beat - MarketBeat
Agios Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Agios Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Agios Pharmaceuticals reports $20.7M revenue, $(1.69) EPS on 10-Q - TradingView
Agios Pharmaceuticals (NASDAQ: AGIO) grows Q1 2026 sales while funding deep rare-disease pipeline - Stock Titan
Earnings call transcript: Agios Q1 2026 earnings soar past expectations By Investing.com - Investing.com Canada
Agios Reports Strong Q1 Revenue Growth and Strategic Advances - GuruFocus
Q1 2026 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings Beat Drives Stock Rally - ChartMill
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Net Loss $1.69 a Share, vs. FactSet Est of $1.80 Loss - marketscreener.com
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q1 Revenue $20.7M, vs. FactSet Est of $13.3M - marketscreener.com
Agios Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals: Q1 Earnings Snapshot - marketscreener.com
Agios (NASDAQ: AGIO) doubles mitapivat revenue and funds 2026 pipeline catalysts - Stock Titan
New thalassemia drug writes 242 U.S. scripts as Agios plans sickle cell filing - Stock Titan
Here's why Agios Pharmaceuticals stock slumped this week (and what investors have to look forward to in 2026) - MSN
Agios Pharmaceuticals (AGIO) Heavy EPS Loss Tests Growth‑Led Bullish Narratives Heading Into Q1 2026 - Sahm
Agios Pharmaceuticals Q1 2026 earnings preview - MSN
Q3 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):